These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30576794)

  • 1. Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients.
    Karsdal MA; Verburg KM; West CR; Bay-Jensen AC; Keller DS; Arends RHGP
    Osteoarthritis Cartilage; 2019 Mar; 27(3):484-492. PubMed ID: 30576794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients.
    Arends RHGP; Karsdal MA; Verburg KM; West CR; Bay-Jensen AC; Keller DS
    Osteoarthritis Cartilage; 2017 Jun; 25(6):866-877. PubMed ID: 28115232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
    Carrino JA; McAlindon TE; Schnitzer TJ; Guermazi A; Hochberg MC; Conaghan PG; Brown MT; Burr A; Fountaine RJ; Pixton GC; Viktrup L; Verburg KM; West CR
    Osteoarthritis Cartilage; 2023 Dec; 31(12):1612-1626. PubMed ID: 37652258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs.
    Cao Z; Zhou J; Long Z; Li Y; Sun J; Luo Y; Wang W
    Aging (Albany NY); 2020 Dec; 13(1):1051-1070. PubMed ID: 33293475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
    Yu Y; Lu ST; Sun JP; Zhou W
    Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study.
    Mont MA; Carrino JA; Nemeth MA; Burr A; Yamabe T; Viktrup L; Brown MT; West CR; Verburg KM
    Surg Technol Int; 2021 May; 38():467-477. PubMed ID: 34043229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
    Miki K; Ohta M; Abe M; Yoshimatsu H; Fujii K; Ebata N; West CR; Brown MT; Pixton G; Isogawa N
    Pain Ther; 2022 Sep; 11(3):827-844. PubMed ID: 35538185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended.
    Pope JE; McCrea K; Stevens A; Ouimet JM
    Med Sci Monit; 2008 Dec; 14(12):CR604-10. PubMed ID: 19043367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WITHDRAWN: Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.
    Towheed TE; Hochberg MC; Shea BJ; Wells G
    Cochrane Database Syst Rev; 2007 Jul; (1):CD000517. PubMed ID: 17636642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanezumab in the treatment of chronic musculoskeletal conditions.
    Jayabalan P; Schnitzer TJ
    Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.
    LaBranche TP; Bendele AM; Omura BC; Gropp KE; Hurst SI; Bagi CM; Cummings TR; Grantham LE; Shelton DL; Zorbas MA
    Ann Rheum Dis; 2017 Jan; 76(1):295-302. PubMed ID: 27381034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials.
    Zhao D; Zeng LF; Liang GH; Pan JK; Luo MH; Han YH; Liu J; Yang WY
    EFORT Open Rev; 2022 Jul; 7(7):470-480. PubMed ID: 35900204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
    Werts A; Reece D; Simon T; Cole P
    Vet J; 2024 Aug; 306():106175. PubMed ID: 38885831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of analgesics in the management of osteoarthritis pain.
    Brandt KD
    Am J Ther; 2000 Mar; 7(2):75-90. PubMed ID: 11319576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.